Illinois General Assembly - Bill Status for HB2850

Home

Legislation & Laws

Senate

House

My Legislation

Site Map

Previous General Assemblies

Bill Status of HB2850 93rd General Assembly

Full Text Votes Witness Slips View All Actions Printer-Friendly Version

Short Description: CIRCUIT BREAKER-RX DRUG REBATE

House Sponsors
Rep. Elizabeth Coulson

Last Action

Date	Chamber	Action
1/11/2005	House	Session Sine Die

Statutes Amended In Order of Appearance

30 ILCS 105/5.595 new

320 ILCS 25/3.15

from Ch. 67 1/2, par. 403.15

320 ILCS 25/4.5 new

Synopsis As Introduced
Amends the State Finance Act and the Senior Citizens and Disabled Persons Property Tax Relief and Pharmaceutical Assistance Act. Provides that beginning July 1, 2004, the Department of Revenue shall by rule expand the classes of drugs covered under the pharmaceutical assistance program beyond those covered as of January 1, 2003, subject to appropriations. Requires the Department to negotiate and enter into agreements with drug manufacturers for rebates in excess of those received by the State as a result of contracts with third parties on January 1, 2003. Provides for the deposit of those rebates and other moneys into the Prescription Drug Assistance Fund, which is created as a special fund in the State treasury, and for the appropriation of moneys in the fund for the purpose of expanding the classes of drugs covered under the pharmaceutical assistance program beyond those covered as of January 1, 2003. Effective immediately.

Fiscal Note (Department of Public Aid)

There will be no additional appropriated cost to the Department of Public Aid. Assuming rebates for prescriptions paid by Medicaid will continue to be deposited into the Drug Rebate Fund, the only potential impact IDPA could be a reduction of the "Best Price" charged by a manufacturer which could reduce the level of federal rebates. There will be administrative costs associated with operating this program. Either a complicated tracking system will need to be developed and staffed, or an outside entity will need to be hired. Additionally, IDOR will pay all but $1.00 for generic and $4.00 for name brand drug prescriptions. Without knowing the number of rule additions or the rebate agreements negotiated, the additional cost of the legislation could not be defined.

Actions

Date	Chamber	Action
2/21/2003	House	Filed with the Clerk by Rep. Elizabeth Coulson
2/21/2003	House	First Reading
2/21/2003	House	Referred to Rules Committee
2/26/2003	House	Assigned to Revenue Committee
3/11/2003	House	Fiscal Note Filed
3/13/2003	House	Rule 19(a) / Re-referred to Rules Committee
1/11/2005	House	Session Sine Die

×